{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:10:56Z","timestamp":1791414656733,"version":"4.3.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,6,8]],"date-time":"2016-06-08T00:00:00Z","timestamp":1465344000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,6,8]],"date-time":"2016-06-08T00:00:00Z","timestamp":1465344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000098","name":"NIH Clinical Center","doi-asserted-by":"publisher","award":["NIH grant CA 62164"],"award-info":[{"award-number":["NIH grant CA 62164"]}],"id":[{"id":"10.13039\/100000098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s00280-016-3063-1","type":"journal-article","created":{"date-parts":[[2016,6,8]],"date-time":"2016-06-08T04:46:43Z","timestamp":1465361203000},"page":"151-156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency"],"prefix":"10.1007","volume":"78","author":[{"given":"Muhammad Wasif","family":"Saif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Diasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,8]]},"reference":[{"key":"3063_CR1","first-page":"432","volume-title":"Cancer: principles and practice of oncology","author":"CJ Allegra","year":"1997","unstructured":"Allegra CJ, Grem JL (1997) Antimetabolites. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 5th edn. Lippincott-Raven, Philadelphia, pp 432\u2013451","edition":"5"},{"key":"3063_CR2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1200\/JCO.1997.15.1.368","volume":"15","author":"AF Sobrero","year":"1997","unstructured":"Sobrero AF, Aschele C, Bertino JR (1997) Fluorouracil in colorectal cancer: a tale of two drugs\u2014Implications for biochemical modulation. J Clin Oncol 15:368\u2013381","journal-title":"J Clin Oncol"},{"key":"3063_CR3","first-page":"149","volume-title":"Cancer chemotherapy and biotherapy: principles and practice","author":"JL Grem","year":"1996","unstructured":"Grem JL (1996) 5-Fluoropyrimidines. In: Chabner BA, Longo DL (eds) Cancer chemotherapy and biotherapy: principles and practice. Lippincott-Raven, Philadelphia, pp 149\u2013211"},{"key":"3063_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3816\/CCC.2004.n.018","volume":"4","author":"H Ezzeldin","year":"2004","unstructured":"Ezzeldin H, Diasio R (2004) Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer 4:181\u2013189","journal-title":"Clin Colorectal Cancer"},{"key":"3063_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0065-2571(00)00011-X","volume":"41","author":"MR Johnson","year":"2001","unstructured":"Johnson MR, Diasio R (2001) Importance of dihydropyrimidine dehydrogenase (DYPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzyme Regul 41:151\u2013157","journal-title":"Adv Enzyme Regul"},{"key":"3063_CR6","first-page":"4705","volume":"12","author":"AB Van Kuilenburg","year":"2000","unstructured":"Van Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, DeAbreu RA, Maring JG, Vreken P, Van Gennip AH (2000) Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity; identification of new mutations in the DPD gene. Clin Cancer Res 12:4705\u20134712","journal-title":"Clin Cancer Res"},{"key":"3063_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1172\/JCI113308","volume":"81","author":"RB Diasio","year":"1988","unstructured":"Diasio RB, Beavers TL, Carpenter JT (1988) Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Investig 81:47\u201351","journal-title":"J Clin Investig"},{"key":"3063_CR8","first-page":"2006","volume":"5","author":"MR Johnson","year":"1999","unstructured":"Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB (1999) Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient following treatment with topical 5-fluorouracil. Clin Cancer Res 5:2006\u20132011","journal-title":"Clin Cancer Res"},{"key":"3063_CR9","first-page":"3964","volume":"42","author":"DS Martin","year":"1982","unstructured":"Martin DS, Stolfi RL, Sawyer RC, Spiegelman S, Young CW (1982) High-dose 5 fluorouracil with delayed \u201curidine\u201d rescue in mice. Cancer Res 42:3964\u20133970","journal-title":"Cancer Res"},{"key":"3063_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/BF00292865","volume":"8","author":"P Klubes","year":"1982","unstructured":"Klubes P, Cerna I, Meldon MA (1982) Uridine rescue from the lethal toxicity of 5-fluorouracil in mice. Cancer Chemother Pharmacol 8:17\u201321","journal-title":"Cancer Chemother Pharmacol"},{"key":"3063_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/BF00254098","volume":"24","author":"DS Martin","year":"1989","unstructured":"Martin DS, Stolfi RL, Sawyer RC (1989) Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine. Cancer Chemother Pharmacol 24:9\u201314","journal-title":"Cancer Chemother Pharmacol"},{"key":"3063_CR12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/0163-7258(89)90111-3","volume":"41","author":"P Klubes","year":"1989","unstructured":"Klubes P, Leyland-Jones B (1989) Enhancement of the antitumor activity of 5-fluorouracil by uridine rescue. Pharmacol Ther 41:289\u2013302","journal-title":"Pharmacol Ther"},{"key":"3063_CR13","first-page":"2543","volume":"43","author":"LD Nord","year":"1992","unstructured":"Nord LD, Stolfi RL, Martin DS (1992) Biochemical modulation of 5-fluorouracil with leucovorin or delayed uridine rescue: correlation of antitumor activity with dosage and FUra incorporation into RNA. Pharmacol 43:2543\u20132549","journal-title":"Pharmacol"},{"key":"3063_CR14","first-page":"5928","volume":"44","author":"A Leyva","year":"1984","unstructured":"Leyva A, van Groeningen CJ, Kraal I, Gall H, Peters GJ, Lankelma J, Pinedo HM (1984) Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity. Cancer Res 44:5928\u20135933","journal-title":"Cancer Res"},{"key":"3063_CR15","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1093\/jnci\/83.6.437","volume":"83","author":"CJ Van Groeningen","year":"1991","unstructured":"Van Groeningen CJ, Peters GJ, Nadal JC, Laurensse E, Pinedo HM (1991) Clinical and pharmacologic study of orally administered uridine. J Natl Cancer Inst 83:437\u2013441","journal-title":"J Natl Cancer Inst"},{"key":"3063_CR16","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1002\/1097-0142(19930301)71:5<1875::AID-CNCR2820710526>3.0.CO;2-9","volume":"71","author":"N Kemeny","year":"1993","unstructured":"Kemeny N, Martin D, Schneider A, Williams L, Colofiore J, Sawyer R (1993) Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-l-aspartate, methotrexate, and leucovorin. Cancer 71:1875\u20131881","journal-title":"Cancer"},{"key":"3063_CR17","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1002\/(SICI)1097-0142(19961101)78:9<1988::AID-CNCR21>3.0.CO;2-T","volume":"78","author":"GK Schwartz","year":"1996","unstructured":"Schwartz GK, Christman K, Saltz L, Casper E, Quan V, Bertino J, Martin DS, Colofiore J, Kelsen D (1996) A phase I trial of a modified, intensive FAMTX regimen (high dose 5-fluorouracil\u00a0+\u00a0doxorubicin\u00a0+\u00a0high-dose methotrexate\u00a0+\u00a0leucovorin) with oral uridine rescue. Cancer 78:1988\u20131995","journal-title":"Cancer"},{"key":"3063_CR18","first-page":"1","volume":"27","author":"MW Saif","year":"2005","unstructured":"Saif MW, von Borstel R (2005) 5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice. Cancer Chemother Pharmacol 27:1\u20137","journal-title":"Cancer Chemother Pharmacol"},{"key":"3063_CR19","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1200\/JCO.1997.15.4.1511","volume":"15","author":"DP Kelsen","year":"1997","unstructured":"Kelsen DP, Martin D, O\u2019Neil J, Schwartz G, Saltz L, Sung MT, von Borstel R, Bertino J (1997) Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer. J Clin Oncol 15:1511\u20131517","journal-title":"J Clin Oncol"},{"key":"3063_CR20","doi-asserted-by":"crossref","unstructured":"Bamat MK, Tremmel R, O\u2019Neil JD et al (2010) Uridine triacetate: an orally administered, lifesaving antidote for 5-FU overdose [ASCO abstract 9084]. J Clin Oncol 28(suppl 15)","DOI":"10.1200\/jco.2010.28.15_suppl.9084"},{"issue":"(Suppl 15)","key":"3063_CR21","doi-asserted-by":"crossref","first-page":"e13505","DOI":"10.1200\/jco.2010.28.15_suppl.e13505","volume":"28","author":"R Von Borstel","year":"2010","unstructured":"Von Borstel R, O\u2019Neil JD, Saydoff JA, Bamat MK (2010) Uridine triacetate for lethal 5-FU toxicity due to dihydropyrimidine dehydrogenase (DPD) deficiency. J Clin Oncol 28(Suppl 15):e13505","journal-title":"J Clin Oncol"},{"key":"3063_CR22","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0378-4347(97)00253-3","volume":"696","author":"MR Johnson","year":"1997","unstructured":"Johnson MR, Yan J, Shao L, Albin N, Diasio RB (1997) Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. J Chromatogr B Biomed Sci Appl 696:183\u2013191","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"3063_CR23","first-page":"5433","volume":"53","author":"Z Lu","year":"1993","unstructured":"Lu Z, Zhang R, Diasio RB (1993) Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53:5433\u20135438","journal-title":"Cancer Res"},{"key":"3063_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1006\/abio.2002.5666","volume":"306","author":"H Ezzeldin","year":"2002","unstructured":"Ezzeldin H, Okamoto Y, Johnson MR, Diasio RB (2002) A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency. Anal Biochem 306:63\u201373","journal-title":"Anal Biochem"},{"issue":"4","key":"3063_CR25","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00280-006-0392-5","volume":"60","author":"MW Saif","year":"2007","unstructured":"Saif MW, Ezzeldin H, Vance K, Sellers S, Diasio RB (2007) DPYD*2A mutation: the most common mutation associated with DPD deficiency. Cancer Chemother Pharmacol 60(4):503\u2013507","journal-title":"Cancer Chemother Pharmacol"},{"issue":"(Suppl 4S)","key":"3063_CR26","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1200\/jco.2016.34.4_suppl.655","volume":"34","author":"WW Ma","year":"2016","unstructured":"Ma WW, Saif WM, El-Rayes BF, Fakih M, Cartwright TH, Posey J, von Borstel R, Bamat MK (2016) Clinical trial experience with uridine triacetate for 5-fluorouracil toxicity. J Clin Oncol 34(Suppl 4S):655","journal-title":"J Clin Oncol"},{"issue":"1","key":"3063_CR27","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1200\/JCO.2000.18.1.167","volume":"18","author":"M Hildalgo","year":"2000","unstructured":"Hildalgo M, Villalona-Calero MA, Eckhardt SG, Drengler RL, Rodriguez G, Hammond LA, Diab SG, Weiss G, Garner AM, Campbell E, Davidson K, Louie A, O\u2019Neil JD, von Borstel R, Von Hoff DD, Rowinsky EK (2000) Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies. J Clin Oncol 18(1):167\u2013177","journal-title":"J Clin Oncol"},{"key":"3063_CR28","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0006-2952(00)00342-7","volume":"60","author":"OM Ashour","year":"2000","unstructured":"Ashour OM, Naguib FN, Panzica RP (2000) Al Safarjalani ON, el Kouni MH. Modulation of 5-fluorouracil host toxicity by 5-(benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2\u2032,3\u2032,5\u2032-tri-O-acetyluridine, a prodrug of uridine. Biochem Pharmacol 60:427\u2013431","journal-title":"Biochem Pharmacol"},{"key":"3063_CR29","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00024427"},{"key":"3063_CR30","first-page":"197","volume":"50","author":"BE Harris","year":"1990","unstructured":"Harris BE, Song R, Soong SJ, Diasio RB (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50:197\u2013201","journal-title":"Cancer Res"},{"issue":"2","key":"3063_CR31","first-page":"89","volume":"10","author":"MW Saif","year":"2013","unstructured":"Saif MW (2013) Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU-and capecitabine-related toxicity using full sequencing of DPYD. Cancer Genom Proteom 10(2):89\u201392","journal-title":"Cancer Genom Proteom"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3063-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-016-3063-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3063-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3063-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T11:22:46Z","timestamp":1589628166000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-016-3063-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,8]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["3063"],"URL":"https:\/\/doi.org\/10.1007\/s00280-016-3063-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,8]]},"assertion":[{"value":"9 March 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}